Skip to main navigation

Top Bar

  • info@eledon.com
  • +1 949.238.8090
Eledon Pharmaceuticals - logo

Main navigation

  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Governance
  • R&D
    • R&D Overview
    • CD40L Pathway
    • Pipeline
    • AT-1501
    • Phase 1 KLH Challenge
  • Investors
    • News
    • Events
    • Presentations
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
    • Contact
  • Join the team
  • Contact Us

Investors

Investor Relations

  • Investors
  • News
  • Events
  • Presentations
  • Stock Information
  • Analyst Coverage
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Contact Investor Relations
  • Ethics Hotline

News


Date Title
01/09/2023 Summary ToggleeGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
01/09/2023 Summary ToggleEledon Pharmaceuticals Provides Business and Pipeline Updates
12/21/2022 Summary ToggleC-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
11/14/2022 Summary ToggleEledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
11/03/2022 Summary ToggleEledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
10/24/2022 Summary ToggleEledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
10/03/2022 Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Conferences
09/22/2022 Summary ToggleEledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
09/06/2022 Summary ToggleEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
08/29/2022 Summary ToggleEledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 122 results

Toolkit

Print Page Email Alerts RSS Feeds Contact

Footer

Quick links

  • Home
  • About Us
  • CD40L Pathway
  • Pipeline
  • AT-1501
  • KLH Challenge
  • Contact Us

Footer Investor Links

  • Investors
  • Press Releases
  • Governance
  • Stock Information
  • SEC Filings
  • Investor Email List
© 2023 Eledon Pharmaceuticals, Inc. - All Rights Reserved.